Identification of the bona fide active center of influenza A virus polymerase acidic protein as the antiviral target
Tong, Y.; Xu, S.; Wang, X.; Zhang, L.; Tu, Y.; Wu, Y.; Du, S.; Wang, W.
Show abstract
The influenza virus PA protein, a core subunit of RNA polymerase, is critical for viral replication and a key antiviral target. Contrary to the prevailing view that its endonuclease active site resides in the N-terminal domain (PAn, residues 1-319), we identified a C-terminal truncation (PAc, 320-716) of H1N1 PA that retained high endonuclease activity, while PAn showed minimal activity. Crystal structural analysis revealed that PAc binds substrate RNA via the YDS motif (residues 393-395), with mutations abolishing RNA association. Surprisingly, baloxavir acid (BXA), a known PA inhibitor, specifically targeted PAc rather than PAn, supported by molecular docking showing higher binding affinity to PAc. Mutations at PAc-BXA interaction sites identified F707A as a potential drug resistance mutation. Virtual screening targeting PAc identified methotrexate as potent inhibitors (EC50 < 100 nM), which effectively suppressed viral replication in vitro and alleviated symptoms in influenza-infected mice. Our findings redefine PAs catalytic architecture and establish PAc as a novel platform for antiviral discovery, offering strategies to combat drug resistance through structure-guided inhibitor design.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Novel and potent inhibitors targeting DHODH, a rate-limiting enzyme in de novo pyrimidine biosynthesis, are broad-spectrum antiviral against RNA viruses including newly emerged coronavirus SARS-CoV-2 96%
- Comprehensive analysis of RNA-seq and whole genome sequencing data reveals no evidence for SARS-CoV-2 integrating into host genome 92%
- Structural and molecular basis for foot-and-mouth disease virus neutralization by two potent protective antibodies 91%
Similar papers in this journal
Similar papers in this journal
- An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants 94%
- ACE2-Targeting Monoclonal Antibody as Potent and Broad-Spectrum Coronavirus Blocker 93%
- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Membrane (M) Protein Inhibits Type I and III Interferon Production by Targeting RIG-I/MDA-5 Signaling 93%
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.